Global Fashion Group S.A.

  • WKN: A2PLUG
  • ISIN: LU2010095458
  • Land: Luxemburg

Nachricht vom 27.08.2019 | 12:15

DGAP-DD: Global Fashion Group S.A. english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

27.08.2019 / 12:15
The issuer is solely responsible for the content of this announcement.


NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM

 

1.1.1.1 Details of the person discharging managerial responsibilities/person

closely associated
1.1.1.2 Name1 Partan Limited
 
2. Reason for the notification
2.1 Position / status2 n/a
2.2 Initial notification /

amendment3
PCA to Cynthia Gordon, Chairman of the Supervisory Board of Global Fashion Group S.A.
 
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
3.1 Name Global Fashion Group S.A.
3.2 LEI Hargreaves Lansdown  
 
4. Details of the transaction(s)
section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
4.1 Description of the
financial instrument, type of instrument 6
Order to trade shares
Identification code GFG.DE (LU2010095458)
4.2 Nature of the

transaction8
Purchase of shares
4.3 Price(s) and volume(s)9 Price(s) Volume(s)
2.7917 EUR 4,000
  Aggregated  
  information
  - Aggregated

volume10
4,000
4.4 - Price11 EUR 11,166.80
4.5 Date of the

transaction12
23/08/2019 (08:49am)
4.6 Place of the

transaction13
United Kingdom


27.08.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktuelle Research-Studie

Original-Research: Rapid Dose Therapeutics Corp. (von Sphene Capital GmbH): Buy Rapid Dose Therapeutics Corp.

15. Oktober 2019